Patricia Devaux, Ph.D., is testing a new technology to reprogram human blood cells to go back to a state from which they can then develop into other kinds of cells, particularly insulin-producing cells for the treatment of diabetes.
Her research focuses on the development of a new platform to reprogram the cells. This platform is based on a strain of the Measles virus. As the measles vaccine is one of the safest vaccines in human history, the use of this vaccine will lead to the safe modification of the cells without the risk of tumor development.
The goal of Dr. Devaux's research is to advance the science in the area of regenerative medicine. Regeneration of transplantable tissues from autologous stem cells is an enormous step forward in individualized cell therapy for various degenerative diseases.
Dr. Devaux is an Assistant Professor of Biochemistry and Molecular Biology at Mayo Clinic. She is also a researcher with the Gene and Virus Therapy Program, Center for Regenerative Medicine, Mayo Clinic Cancer Center, and Molecular Medicine.
Learn more about Dr. Devaux's research: